News

The Danish drugmaker said the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, and reached a further two million prescriptions in the following 10 weeks.

Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough sell with Novo Nordisk (NVO) and Eli Lilly (LLY) already owning the narrative with blockbuster ...

Novo Nordisk could maintain this latest early-mover advantage longer than you think.

Novo Nordisk (CPSE:NOVO B) reported positive phase 2 data for its investigational drug amycretin (zenagamtide), a dual GLP-1 and amylin receptor agonist. The phase 2 trial in adults with type 2 diabetes showed strong glycemic control and significant weight loss, with no clear plateau at higher doses. Safety and efficacy data support moving amycretin into phase 3 trials for both diabetes and obesity. This is the first major update on this new pipeline candidate as Novo Nordisk seeks to...

Investing.com -- Pfizer Inc (NYSE:PFE) has unveiled detailed strategy plans and clinical data for its experimental weight-loss injection, aiming to secure a foothold in a competitive market currently dominated by rivals. The New York-based pharmaceutical giant is working to catch up to industry leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), which have captured significant market share through their first-mover advantages. Following earlier clinical setbacks, Pfizer rev

Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.

Both drugmakers are expanding internationally as pricing and access remain major barriers.

TD Cowen raises its 2030 GLP-1 sales forecast as Lilly and Novo are expected to keep dominant market shares.

Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer mentioned the stock while discussing the woes of the healthcare industry, as he said: Next worst is healthcare. Oh, this group has just been annihilated. I’ve never seen it trading this bad […]

LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.

TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.

Novo Nordisk (CPSE:NOVO B) has signed a clinical supply agreement with Veru Inc. to provide Wegovy for a Phase 2b obesity trial in older adults. The PLATEAU study will test Wegovy alongside Veru’s enobosarm, a selective androgen receptor modulator, in combination therapy. Novo Nordisk retains no development rights to enobosarm but has secured a right of first negotiation for potential future collaborations with Veru. For investors tracking CPSE:NOVO B, this agreement comes as the share...

Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.

Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for obesity in older adults.

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

A share price rally pushed ASML's market cap to $668 billion on Wednesday, beating a European record set by Novo Nordisk in June 2024.

The Dutch chipmaker eclipses Novo Nordisk's 2024 peak as AI infrastructure demand drives a 130% rally.

Danske Bank lifts Denmark outlook again as Novo Nordisk demand supports export growth.

There is light at the end of the tunnel.

Novo Brings Oral Obesity Drug To UAE Patients

European stock markets closed lower Wednesday as the Stoxx Europe 600 fell 0.7%, Germany's DAX 40 sh

A launch in the United Arab Emirates comes as Novo works to recover ground in the weight loss drug market against rival Eli Lilly

Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it’s prescribed, not faddish. So this is the next 90-million-customer industry, sitting in plain sight while everyone ... 5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Novo Nordisk (NYSE:NVO) has introduced the tablet form of its blockbuster obesity treatment Wegovy in the United Arab Emirates, marking the second country worldwide to receive the oral version of the medication. The launch follows regulatory approval granted earlier this week by health authorities in the UAE and comes several months after the Danish pharmaceutical group debuted the product in the United States.

Novo Nordisk (CPSE:NOVO B) has launched the Wegovy pill in the UAE, the first country outside the U.S. to offer this oral obesity treatment. Regulators in the EU have issued positive opinions recommending approval of both the Wegovy pill and a higher dose injectable formulation. The company is expanding obesity care access through partnerships, including a collaboration with NOVI Health in Singapore. Novo Nordisk, through CPSE:NOVO B, is a major player in obesity and diabetes care, and...

The UAE launch marks the start of Novo's global rollout, with additional launches planned later this year.

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.